Metastasis-directed Therapy for Oligorecurrent Prostate Cancer: a Randomized Phase III Trial
Status:
Active, not recruiting
Trial end date:
2032-04-25
Target enrollment:
Participant gender:
Summary
The aim is to investigate whether the addition of short-term androgen deprivation therapy
(ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor
targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs
poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer
free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.